



New Biomarkers in Thyroid Cancer and Autoimmune Diseases

Guest Editor:

Dr. Karolina H. Czarnecka-Chrebelska

Department of Biomedicine and Genetics, Medical University of Lodz, Lodz, Poland

Deadline for manuscript submissions:

closed (31 October 2023)

Message from the Guest Editor

Dear Colleagues,

Thyroid cancer is a complex disease with multiple subtypes, each with a distinct set of driver mutations such as BRAF, TERT, p53, RET, and RAS. Identifying these mutations is crucial for accurate diagnosis, prognosis, and targeted therapy. Thyroid cancer exhibits intra-tumor heterogeneity, which can complicate genetic analysis and the interpretation of results. In addition to genetic mutations, epigenetic changes such as DNA methylation and histone modification can contribute to thyroid cancer development and progression. Despite significant progress in understanding the genetic basis of thyroid cancer, translating this knowledge into clinical practice remains a challenge. More research is needed to develop effective targeted therapies and improve patient outcomes.

We invite research papers that will consolidate our understanding of the biology of thyroid cancer and how prolonged inflammation can impact cancerogenesis. The Special Issue will publish full research articles and comprehensive reviews on all aspects related to the theme of thyroid cancer and autoimmune diseases, including new biomarkers.





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and
Center for Clinical Research
Learning, Spaulding
Rehabilitation Hospital and
Massachusetts General Hospital,
Harvard Medical School, Boston,
MA 02114, USA
2. Department of Epidemiology,
Harvard T.H. Chan School of
Public Health, Boston, MA 02115,
USA

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility: indexed within *Scopus*, *SCIE (Web of Science)*, *PubMed*, *PMC*, *CAPlus / SciFinder*, and other databases.

Journal Rank: JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q2 (*Medicine (miscellaneous)*)

Contact Us

Biomedicines Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/biomedicines
biomedicines@mdpi.com
[X@Biomed_MDPI](https://twitter.com/Biomed_MDPI)